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Objective: To investigate the efﬁcacy of low-level laser therapy (LLLT) treatment of knee osteoarthritis
(KOA) by a systematic literature search with meta-analyses on selected studies.
Design: MEDLINE, EMBASE, ISI Web of Science and Cochrane Library were systematically searched from
January 2000 to November 2014. Included studies were randomized controlled trials (RCTs) written in
English that compared LLLT (at least eight treatment sessions) with sham laser in KOA patients. The
efﬁcacy effective size was estimated by the standardized mean difference (SMD). Standard ﬁxed or
random-effects meta-analysis was used, and inconsistency was evaluated by the I-squared index (I2).
Results: Of 612 studies, nine RCTs (seven double-blind, two single-blind, totaling 518 patients) met the
criteria for inclusion. Based on seven studies, the SMD in visual analog scale (VAS) pain score right after
therapy (RAT) (within 2 weeks after the therapy) was not signiﬁcantly different between LLLT and control
(SMD ¼ 0.28 [95% CI ¼ 0.66, 0.10], I2 ¼ 66%). No signiﬁcant difference was identiﬁed in studies
conforming to the World Association of Laser Therapy (WALT) recommendations (four studies) or on the
basis of OA severity. There was no signiﬁcant difference in the delayed response (12 weeks after end of
therapy) between LLLT and control in VAS pain (ﬁve studies). Similarly, there was no evidence of LLLT
effectiveness based on Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain,
stiffness or function outcomes (ﬁve and three studies had outcome data right after and 12 weeks after
therapy respectively).
Conclusion: Our ﬁndings indicate that the best available current evidence does not support the effec-
tiveness of LLLT as a therapy for patients with KOA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
There are still no disease-modifying treatments for knee osteo-
arthritis (KOA). The currently available options include palliative
pharmacological andnon-pharmacologicalmodalities. The core goal
of these treatments is to relieve joint pain, improve joint function
and gain a better quality of life. Though nonsteroidal anti-.B. Kraus, Division of Rheumatolog
ke St, Durham, NC 27701-2047, U
F. Pei, Department of Orthopedic
ople's Republic of China. Tel: 86-1
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ternational. Published by Elsevier Linﬂammatory drugs (NSAIDs) are widely used to treat these
patients, their high incidence of side effects, especially of the upper
gastrointestinal tract, has limited their use1. Thus, many physical
therapy agents such as ultrasound2, electrical stimulation3,
strengtheningexercise4 and thermal therapy5 havebeen introduced.
Because of its non-invasiveness and advantage of inciting
nearly no adverse side effects, low-level laser therapy (LLLT) hasy, Duke University School of Medicine, Duke Molecular Physiology Institute, PO Box
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disorders6,7. It has been considered a promising therapeutic
intervention, mainly because of its stimulatory effects on tissue
metabolism and ability to modulate the inﬂammatory process
after injury. Some reported effects include improved cellular
oxygenation, release of neurotransmitter associated with pain
modulation and release of anti-inﬂammatory, endogenous medi-
ators8. Nonetheless, reported clinical therapeutic outcomes are
conﬂicting. Studies are similarly conﬂicting regarding its usage in
patients with KOA9,10.
Recently there has been an increased number of randomized
controlled trials (RCTs) assessing the effectiveness of LLLT inpatients
withKOA; theyhavenotyet been integrated intoa systematic review
or meta-analysis. Therefore, the aim of this study was to evaluate,
through a systematic review andmeta-analysis, the effectiveness of
LLLT on symptoms and function in patients with KOA.
Method
Search strategy and study selection
The following bibliographic databases were searched up to 11th
November 2014: Medline via PubMed from 2000, EMBASE via OVID
from 2000, Web of Science from 2000 as well as the Cochrane
Central Register of Controlled Trials. The search strategy was:
(Osteoarthritis OR osteoarthros*) AND (knee) AND (low-level laser
therapy OR low intensity laser therapy OR low energy laser therapy
OR LLLT OR LILT OR LELT OR infrared laser OR IR laser OR diode
laser).
Two reviewers independently identiﬁed titles and abstracts
relevant to applying LLLT to patients suffering from KOA. Full texts
of the published articles, unpublished articles as well as unpub-
lished data of completely ﬁnished and analyzed studies were
included. The reference list of the full-text articles was also
reviewed. To be included in this analysis, studies had to meet the
following criteria: (1) be RCTs; (2) involve patients with KOA (as
assessed with radiography or according to the American College of
Rheumatology guidelines); (3) compare LLLT and placebo laser; (4)
report pain and/or function outcomes of patients; (5) attain a PEDro
score11 of >5; and (6) be written in English. Trials with an unbal-
anced additional modality (e.g., education or exercise) between
groups were excluded.
Quality assessment
Two independent reviewers assessed study quality or risk of
bias in each study using the PEDro scale11. The 11-point PEDro scale
has been accepted as a reliable12 and valid13 assessment tool and is
the one most often employed for physical treatments. Brieﬂy, a
study with a score of 7 is considered to be of high methodological
quality, while a study with a score of 5 is considered to be of low
methodological quality. The methodological assessment was con-
ducted by two independent reviewers and results compared. Dis-
crepancies between the two independent reviewers were resolved
by consensus after discussion, and a third reviewer was consulted if
necessary.
Data extraction
Study data were extracted by two reviewers and checked for
accuracy by a third reviewer including the intervention description,
inclusion/exclusion criteria, baseline data, values for all outcomes
at baseline, post-intervention and later follow-up (12 weeks). Theprimary outcomes of interest were the visual analog scale (VAS)
pain scores (right after the intervention meaning within 2 weeks
after the ﬁnal therapy session), expressed in millimeters, and the
Western Ontario and McMaster Universities Arthritis Index
(WOMAC) scores (pain, stiffness, function and total; right after the
intervention). The secondary outcomes of interest were range of
motion (ROM) right after therapy (RAT), and VAS pain andWOMAC
scores (pain, stiffness and function) at or near 12 weeks after
therapy. If the data were not presented in the study as mean and
standard deviation, or were presented in a form that prevented
calculation of mean and standard deviation, the original authors
were contacted.
Statistical analysis
We performed the meta-analysis in conformance with the
Cochrane Collaboration and the Quality of Reporting of Meta-
analysis guidelines. Because all the primary and secondary out-
comes were continuous outcome data, means and standard de-
viations were used to calculate a standard mean difference (SMD)
and 95% conﬁdence interval (CI) in the meta-analysis. We checked
all results for clinical and statistical heterogeneity. Clinical hetero-
geneity, determined by Chi-squared test, was evaluated based on
the study baseline, interventions, deﬁnition of outcome measures,
concomitant treatment and follow-up. A P value <0.05 was
considered signiﬁcantly different. I2 values were used for the
evaluation of statistical heterogeneity (I2-of 50% or more indicating
presence of heterogeneity)14,15. We used a standard random-effects
meta-analysis for the main analyses. Results right after therapy
refer to the comparison of LLLT and placebo after the series of
therapy sessions raging from 8 to 20 over 2e6 weeks. Results after
12 weeks of therapy refer to the evaluation of a delayed or main-
tained response approximately 12 weeks after the last treatment
session. A ﬁxed-effects model was applied for the purpose of
sensitivity analysis. Data were presented as a forest plot. We
analyzed the effect of LLLT in subgroups distinguished by adher-
ence to World Association of Laser Therapy (WALT) guidelines16,17
and KOA severity18. Analyses were conducted using Review Man-
ager Version 5.3 for MAC (The Nordic Cochrane Centre, The
Cochrane Collaboration).
Results
Study selection and characteristics
Figure 1 illustrates the selection process for including studies in
this meta-analysis. In total, 612 potential studies were found. Based
on the title and abstract content, 595 of these studies were
excluded. The full texts of the remaining 17 studies were read, and a
further eight studies were excluded, resulting in nine studies19e27
retained in the qualitative and quantitative synthesis of this re-
view. A total of 518 patients were included: 264 patients in the LLLT
group and 254 patients in the placebo group. In keeping with the
WALT recommendations16,17, each of these studies provided at least
eight therapy sessions (range 8e20) over the course of 2e6 weeks.
The characteristics of the included studies are listed in Tables I and
II. Each of these studies included a placebo laser arm consisting of
sham laser. The methodological quality assessment (Supplemental
Table 1) showed that all these nine studies were of high quality
(PEDro score of 7). All outcomes with appropriately reported data
were extracted and included in the meta-analysis. Outcome mea-
sures were grouped according to their construct and design
(Tables III and IV).
Fig. 1. CONSORT diagram showing screening process and search results.
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Pain relief
Right after therapy, LLLT was not superior to placebo whether
assessed by the VAS pain scale (SMD¼0.28 [95% CI¼0.66, 0.10],
I2 ¼ 66%) (Fig. 2) or by WOMAC pain score (SMD ¼ 0.25 [95%
CI ¼ 0.88, 0.37], I2 ¼ 79%) (Fig. 3). Subgroup analysis based on
whether the studies were performed according to the WALT rec-
ommendations showed no signiﬁcant difference between the two
interventions in terms of VAS or WOMAC pain score right after
therapy (Figs. 2 and 3). Moreover, another subgroup analysis based
on the severity of OA (inclusion of patients with Kell-
greneLawrence grade IV KOA) also did not identify any signiﬁcant
differences between LLLT and placebo treatment (Supplemental
Figs. 1 and 2). Analysis of the pooled data from week 12 after
therapy also did not support the superiority of LLLT over placebo at
this timepoint based on VAS pain (ﬁve pooled studies yielded
SMD ¼ 0.06 [95% CI ¼ 0.30, 0.18], I2 ¼ 44%) (Table V) and
WOMAC pain score (three pooled studies yielded SMD ¼ 0.01, [95%
CI ¼ 0.27, 0.29], I2 ¼ 29%) (Table V).WOMAC stiffness score
Five19,21,25e27 (Table IV) of the included studies provided data
on WOMAC stiffness score right after therapy. The meta-analysis
showed no signiﬁcant difference between the two groups
(SMD ¼ 0.07 [95% CI ¼ 0.35, 0.21], I2 ¼ 48%) (Supplemental
Fig. 3). The WOMAC stiffness score at week 12 after therapy
was mentioned in only two studies20,27 (Table IV); these pooled
studies failed to identify a signiﬁcant difference between the two
treatment groups (SMD ¼ 0.17 [95% CI ¼ 0.24, 0.58], I2 ¼ 31%)
(Table V).
WOMAC function score
Data on the WOMAC function score right after therapy were
available in ﬁve studies19,20,25e27; data on the WOMAC function
score at week 12 after therapy were available in three
studies20,24,27 (Table IV). The combined results showed no sig-
niﬁcant difference between LLLT and placebo groups at either
timepoint (SMD ¼ 0.40 [95% CI ¼ 1.23, 0.43], I2 ¼ 88%
(Supplemental Fig. 5); SMD ¼ 0.10 [95% CI ¼ 0.33, 0.53],
I2 ¼ 53% (Table V)).
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Table II
Severity of OA in included studies
Studies Group Severity of OA
Grade II Grade III Grade IV
Gur et al., 2003 LLLT Group 14 10 6
Placebo Group 13 11 6
Tascioglu et al., 2004 LLLT Group 12 8 0
Placebo Group 11 9 0
Yurtkuran et al., 2007 LLLT Group Patients with KellgreneLawrence
Grade II and IIIPlacebo Group
Alfredo et al., 2011 LLLT Group 4 9 7
Placebo Group 9 4 7
Fukuda et al., 2011 LLLT Group 31 8 2
Placebo Group 27 9 2
Alghadir et al., 2014 LLLT Group 16 4 0
Placebo Group 17 3 0
Kheshie et al., 2014 LLLT Group Not provided
Placebo Group
Al Rashoud et al., 2014 LLLT Group 13 5 0
Placebo Group 14 4 0
Hinman et al., 2014 LLLT Group Not provided
Placebo Group
Z. Huang et al. / Osteoarthritis and Cartilage 23 (2015) 1437e14441440ROM right after therapy
Pooled data of three studies20,22,23 (Table IV) on ROM right after
therapy demonstrated no statistical difference between the two
groups (SMD ¼ 0.35 [95% CI ¼ 0.75, 1.45], I2 ¼ 90%) (Table V).
Discussion
Pain is the most common reason for persons with chronic
musculoskeletal disorders to seek medical assistance. LLLT was
introduced to control symptoms in a non-invasive manner with
nearly no adverse effects and at low cost. However, the outcomes of
the experimental and clinical studies, including for KOA, are con-
ﬂicting. In 1992, Stelian et al.28 performed an RCT to compare red
(wavelength 630 nm), infrared (wavelength 830 nm) and placebo
laser light emitters in patients with KOA. They observed signiﬁcant
functional improvement and pain reduction in the red and infrared
groups but not in the placebo group. Soon, several additional
studies were undertaken to evaluate the effectiveness of LLLT in
KOA patients. In a double blind placebo controlled study, Bulow
et al.29 found there was no signiﬁcant difference between LLLT and
placebo treated groups for any outcome measures related to pain,
strength or joint activity. Subsequently, Tascioglu et al.26 also failed
to observe any advantages of LLLT. These studies cast doubt on the
effectiveness of LLLT in KOA patients. Recently, several high-quality
RCTs have emerged in this ﬁeld. Since no study has synthesized the
results in a meta-analysis, we performed the current analysis,
including nine studies with 518 patients. Themeta-analysis showed
no therapeutic beneﬁt of LLLT compared with placebo for KOA pa-
tients with respect to pain relief or functional improvement,
including right after therapy or at week 12 after therapy.
Potential mechanisms of pain reduction by laser therapy are still
unknown. Several experimental studies suggest that LLLT has anti-
inﬂammatory and/or analgesic effects. Some posit that LLLT could
inhibit nociceptive signals at peripheral nerves30. Others believe
LLLT could increase oxygenation of the tissue, thus alleviating and
removing swelling, which could result in reduced pain21. Certain
studies31,32 reported enhanced joint cartilage regeneration after
LLLT. However, the results of the interaction of laser light with the
tissue depend on several factors such as the energy density,
wavelength, output, number and timing of treatment sessions as
well as the optical properties of the tissue.
Several studies using LLLT for musculoskeletal pain have shown
that the greatest laser photobiomodulation effectiveness appears to
Table III
Technical features of laser use in the included for meta-analysis
Studies Laser type Laser model
(manufacture)
Treatment time/No. of total
sessions/No. of sessions per week
Laser continuous
output (average pulse)
Energy density
(J/cm2)
Energy per point
(J/point per session)
Gur et al., 2003 GaeAs 904 nm Frank Line IR 30 5 min/10/5 10 mW 3 3
Tascioglu et al., 2004 GaleAleAs 830 nm Endolaser 476 120 s/20/5 50 mW 0.76 0.6
Yurtkuran et al., 2007 GaeAs 904 nm Roland Serie 120 s/10/5 4 mW 1.2 0.48
Alfredo et al., 2011 GaeAs 904 nm Irradia Class 3B 50 s/9/3 60 mW 6 3
Fukuda et al., 2011 GaeAs 904 nm Irradia Class 3B 50 s/9/3 60 mW 6 3
Alghadir et al., 2014 GaeAs 850 nm Intellect 60 s/8/2 100 mW 48 6
Kheshie et al., 2014 GaeAs 830 nm BTL-5000 33 s/12/2 800 mW 50 NA
Al Rashoud et al., 2014 GaeAs 830 nm Endolaser 476 40 s/9/3 30 mW 4 1.2
Hinman et al., 2014 NA Standard Class 3B 20 min/8/2 10 mW NA 0.2
Abbreviation: NA, not available; min, minute; s, second.
Table IV
Description of outcome measures used in the studies included in the meta-analysis
Studies Outcome measures
Pain Stiffness Function
Gur et al., 2003 1. VAS pain (RAT, eighth, twelfth week)
2. Painless walking duration (min)
(RAT, eighth, twelfth week)
3. Painless walking distance (m)
(RAT, eighth, twelfth week)
1. Morning stiffness (min)
(RAT, eighth, twelfth week)
1. ROM (RAT, eighth, twelfth week)
Tascioglu et al., 2004 1. VAS pain (RAT, sixth month)
2. WOMAC pain (RAT, sixth month)
1. WOMAC stiffness (RAT, sixth month) 1. WOMAC function (RAT, sixth month)
Yurtkuran et al., 2007 1. VAS pain (RAT, twelfth week)
2. WOMAC pain (RAT, twelfth week)
1. WOMAC stiffness (RAT, twelfth month) 1. WOMAC function (RAT, twelfth week)
Alfredo et al., 2011 1. VAS pain (RAT, eleventh week)
2. WOMAC pain (RAT, eleventh week)
1.WOMAC Stiffness (RAT, eleventh week) 1. ROM (RAT, eleventh week)
2. WOMAC Function (RAT, eleventh week)
Fukuda et al., 2011 1. VAS pain (RAT) NA 1. ROM (RAT)
Alghadir et al., 2014 1. VAS pain (RAT)
2. WOMAC pain (RAT)
1. WOMAC Stiffness (RAT) 1. WOMAC Function (RAT)
Kheshie et al., 2014 1. WOMAC pain (RAT) 1. WOMAC Stiffness (RAT) 1. WOMAC Function (RAT)
Al Rashoud et al., 2014 1. VAS pain (RAT, sixth week, sixth month) NA NA
Hinman et al., 2014 1. VAS (twelfth week, 1 year)
2. WOMAC pain (twelfth week, 1 year)
NA 1. WOMAC function (twelfth week, 1 year)
NA: Not available.
Z. Huang et al. / Osteoarthritis and Cartilage 23 (2015) 1437e1444 1441be linked to higher irradiation protocols (energy density) as well as
to a greater number of sessions and frequency of application. By
comparing several previous clinical trials, Fukuda et al.22 and
Alghadir et al.21 concluded that only applications of an LLLT energy
density greater than 3 J/point could be effective. According to the
WALT16,17 table of recommended doses, the optimal energy density
for KOA is supposed to be a minimum of 4 J per point. Five includedFig. 2. Forest plot analysis of the VAS pain score right after therapy (subgroup anastudies20e22,24,26 followed these WALT recommendations. Even
pooling these four studies, we failed to observe a statistically sig-
niﬁcant difference of LLLT compared to placebo for VAS pain or
WOMAC pain score right after therapy. The WALT guidelines
recommend daily treatment for 2 weeks or treatment every other
day for 3e4 weeks (totaling 6 to 12 sessions). All the included
studies provided or exceeded the recommended session number.lysis based on whether studies conformed to WALT recommendations or not).
Fig. 3. Forest plot analysis of the WOMAC pain score right after therapy (subgroup analysis based on whether studies conformed to WALT recommendations or not).
Z. Huang et al. / Osteoarthritis and Cartilage 23 (2015) 1437e14441442Though Tascioglu et al.26 provided the greatest number of sessions
(20), they still did not observe a difference between LLLT over
placebo.
Wavelength is also considered an essential parameter for
beneﬁcial outcomes of LLLT. Biophysically, it determines the ability
of a laser to penetrate tissue. Light with a wavelength range of
700e1000 nm is infrared and invisible; its ability to penetrate tis-
sue is better than the redwavelength, thus this range of wavelength
is usually used in clinical treatment33. A clinical study of laser
irradiation in skin ﬂaps has shown that penetration increases lin-
early with wavelengths from 450 nm to 1030 nm34. Another study
illustrated that a greater amount of energy penetrated rabbit skin
with a wavelength of 904 nm than with a wavelength of
632.8 nm35. Thus, the WALT guidelines recommend wavelengths of
780 nme860 nm16 or 904 nm17 for LLLT in KOA patients. All the
included studies used a wavelength within this recommended
range.
Besides wavelength, optical properties of tissue are also
believed to be vital to the treatment response to LLLT. The pene-
trability of certain wavelengths varies in different tissues. Accord-
ing to Joensen et al.36, the amount of penetrating light energy is 20%
for a wavelength of 810 nm and 58% for a wavelength of 904 nm.
King et al.37 found that the penetration of laser irradiation into skin
is limited to a fewmillimeters. This might explainwhy some studies
failed to ﬁnd LLLT effective for large joints while the results for
small joints seem promising37.
The severity of the disease is considered a typical host factor
that might affect treatment outcomes38. In a study assessing the
efﬁcacy of LLLT for temporomandibular joint arthritis, Conti et al.39
reported a better outcome in the less severe group. However, up to
now there has been no such study of KOA patients. In this meta-
analysis, we performed a subgroup analysis based on whether theTable V
Meta-analyses of Standard Mean Differences in various continuous parameters between
Parameters No. of patients
LLLT group (n) Placeb
ROM right after therapy 75 72
VAS score at week 12 after therapy 135 126
WOMAC pain score at week 12 after therapy 105 96
WOMAC stiffness score at week 12 after therapy 47 45
WOMAC function score at week 12 after therapy 105 96
* Heterogeneity was determined by Chi-squared test. I2 value was used for the evalu
geneity). Randomized effects model was used when I2  50, otherwise ﬁxed-effects moincluded study enrolled patients with KellgreneLawrence grade IV
KOA. The results did not favor the superiority of LLLT in either the
less or more severely affected subgroups.
As can be seen here, variation in the effectiveness of LLLT in KOA
patients could be related to a variety of factors. At present it is still
difﬁcult to determine the optimal dosage, treatment schedule,
energy density, output and wavelength. This may explain why a
high degree of heterogeneity was observed in several outcomes.
This review has both strengths and limitations. Strengths
include selection of studies, all with high methodological quality
based on the PEDro score. In combining studies with small sam-
ples, we provide the most evidence for effects of LLLT. Additionally,
this meta-analysis was performed on the basis of the Cochrane
Collaboration's principle40 and designed to be rigorous in its
search strategy. Some limitations of the current meta-analysis
warrant discussion. First and foremost is the high degree of het-
erogeneity between the pooled studies. The random-effects model
was chosen due to the presence of this heterogeneity. Second,
several of the included studies used balanced quadriceps exercise
as an additional treatment in both LLLT and placebo groups. Third,
one study reported the continuous data such as VAS pain and
WOMAC scores without SDs. Though we tried to contact the au-
thors to get the information, the missing data could not be ob-
tained; thus, these analyses in some cases did not have full data
available.
Conclusion
The results of our systematic review and meta-analysis have
provided the best current evidence on LLLT in the treatment of KOA.
This study indicated that LLLT has neither early nor later beneﬁts in
reducing pain or improving function in patients with KOA.the LLLT and placebo groups*
Standard mean difference (95% CI) P Value I2
o group (n)
0.32 [0.75, 1.45] 0.54 90%
0.06 [0.30, 0.18] 0.63 44%
0.01 [0.27, 0.29] 0.95 29%
0.17 [0.24, 0.58] 0.42 31%
0.10 [0.33, 0.53] 0.65 53%
ation of statistical heterogeneity (I2- of 50% or more indicating presence of hetero-
del was used.
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